SG10201500404QA - Methods of Treating Diabetes with DLL4 Antagonists - Google Patents
Methods of Treating Diabetes with DLL4 AntagonistsInfo
- Publication number
- SG10201500404QA SG10201500404QA SG10201500404QA SG10201500404QA SG10201500404QA SG 10201500404Q A SG10201500404Q A SG 10201500404QA SG 10201500404Q A SG10201500404Q A SG 10201500404QA SG 10201500404Q A SG10201500404Q A SG 10201500404QA SG 10201500404Q A SG10201500404Q A SG 10201500404QA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- treating diabetes
- dll4 antagonists
- dll4
- antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29980110P | 2010-01-29 | 2010-01-29 | |
| US36168710P | 2010-07-06 | 2010-07-06 | |
| US38869710P | 2010-10-01 | 2010-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201500404QA true SG10201500404QA (en) | 2015-03-30 |
Family
ID=43925413
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201500416RA SG10201500416RA (en) | 2010-01-29 | 2011-01-28 | Methods of Treating Autoimmune Diseases with DLL4 Antagonists |
| SG10201500404QA SG10201500404QA (en) | 2010-01-29 | 2011-01-28 | Methods of Treating Diabetes with DLL4 Antagonists |
| SG2012052056A SG182528A1 (en) | 2010-01-29 | 2011-01-28 | Methods of treating autoimmune diseases with dll4 antagonists |
| SG2012052049A SG182527A1 (en) | 2010-01-29 | 2011-01-28 | Methods of treating diabetes with dll4 antagonists |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201500416RA SG10201500416RA (en) | 2010-01-29 | 2011-01-28 | Methods of Treating Autoimmune Diseases with DLL4 Antagonists |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012052056A SG182528A1 (en) | 2010-01-29 | 2011-01-28 | Methods of treating autoimmune diseases with dll4 antagonists |
| SG2012052049A SG182527A1 (en) | 2010-01-29 | 2011-01-28 | Methods of treating diabetes with dll4 antagonists |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8765125B2 (fr) |
| EP (2) | EP2528946B1 (fr) |
| JP (2) | JP5997613B2 (fr) |
| KR (2) | KR101832118B1 (fr) |
| CN (2) | CN102884081A (fr) |
| AR (1) | AR080026A1 (fr) |
| AU (2) | AU2011210773B2 (fr) |
| BR (2) | BR112012018766A2 (fr) |
| CA (2) | CA2787615C (fr) |
| CY (2) | CY1118223T1 (fr) |
| DK (2) | DK2528945T3 (fr) |
| ES (2) | ES2605430T3 (fr) |
| HR (2) | HRP20170130T1 (fr) |
| HU (2) | HUE032985T2 (fr) |
| IL (2) | IL220887A (fr) |
| JO (2) | JO3183B1 (fr) |
| LT (2) | LT2528945T (fr) |
| MX (2) | MX343553B (fr) |
| MY (2) | MY156538A (fr) |
| PL (2) | PL2528946T3 (fr) |
| PT (2) | PT2528945T (fr) |
| RS (2) | RS55595B1 (fr) |
| RU (2) | RU2587620C2 (fr) |
| SG (4) | SG10201500416RA (fr) |
| SI (2) | SI2528945T1 (fr) |
| SM (2) | SMT201600412B (fr) |
| TW (2) | TWI564019B (fr) |
| UY (1) | UY33206A (fr) |
| WO (2) | WO2011094465A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| EP3029070A1 (fr) | 2009-08-29 | 2016-06-08 | AbbVie Inc. | Protéines de liaison dll4 thérapeutiques |
| ES2895226T3 (es) | 2009-10-16 | 2022-02-18 | Mereo Biopharma 5 Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| MY160628A (en) | 2010-03-02 | 2017-03-15 | Abbvie Inc | Therapeutic DLL4 Binding Proteins |
| BR112014007035B1 (pt) | 2011-09-23 | 2021-05-04 | Oncomed Pharmaceuticals, Inc | anticorpos biespecíficos que se ligam a vegf/dll4, composição farmacêutica e célula procariótica, fúngica ou de levedura que compreende os mesmos, moléculas de polinucleotídeo, vetor, usos terapêuticos e método para a produção de um anticorpo |
| KR101535341B1 (ko) * | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| KR20210111353A (ko) | 2012-11-01 | 2021-09-10 | 애브비 인코포레이티드 | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 |
| TW201438736A (zh) * | 2012-11-14 | 2014-10-16 | Regeneron Pharma | 以ｄｌｌ４拮抗劑治療卵巢癌之方法 |
| EP3020731B1 (fr) | 2013-07-09 | 2019-06-12 | ABLBio | Nouvelles protéines à double cible se liant spécifiquement à dll4 et vegf et leur utilisation |
| CN111239415B (zh) * | 2013-10-17 | 2024-03-26 | 综合医院公司 | 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物 |
| WO2015154795A1 (fr) * | 2014-04-08 | 2015-10-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Polythérapie pour le traitement de maladies auto-immunes |
| DK3212233T3 (da) | 2014-10-31 | 2020-07-27 | Oncomed Pharm Inc | Kombinationsterapi til behandling af sygdom |
| AU2016326609B2 (en) | 2015-09-23 | 2023-03-09 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| EP3886856A4 (fr) * | 2018-11-29 | 2022-01-19 | Zucco Sassi Yonezawa Siviglia, Debora | Procédé de traitement ou de prévention de crises associées à un trouble épileptique |
| US11446262B2 (en) | 2018-11-29 | 2022-09-20 | Debora Zucco Sassi Yonezawa Siviglia | Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination |
| WO2022210802A1 (fr) * | 2021-03-30 | 2022-10-06 | 国立大学法人熊本大学 | Agent thérapeutique pour l'atrophie musculaire |
| WO2023159166A1 (fr) * | 2022-02-18 | 2023-08-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Anticorps à domaine unique (nanocorps) ciblant le ligand notch dll4 et leurs méthodes d'utilisation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| BR0311161A (pt) * | 2002-05-21 | 2005-03-29 | Cv Therapeutics Inc | Método de tratamento de diabetes |
| WO2005103081A2 (fr) | 2004-04-20 | 2005-11-03 | Genmab A/S | Anticorps monoclonaux humains diriges contre cd20 |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| AU2006326417B2 (en) * | 2005-12-16 | 2012-05-24 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with Dll4 antagonists |
| CN102585002A (zh) | 2006-06-02 | 2012-07-18 | 瑞泽恩制药公司 | 人il-6受体的高亲和力抗体 |
| KR20090027227A (ko) * | 2006-06-06 | 2009-03-16 | 제넨테크, 인크. | 항-ｄｌｌ4 항체 및 이의 사용 방법 |
| WO2007143689A2 (fr) | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions et procédés destinés à moduler le développement vasculaire |
| WO2008019144A2 (fr) | 2006-08-07 | 2008-02-14 | Regeneron Pharmaceuticals, Inc. | Procédés thérapeuthiques pour traiter des troubles vasculaires de l'oeil par des antagonistes de dll4 |
| MX2009003229A (es) | 2006-09-29 | 2009-06-18 | Oncomed Pharm Inc | Composiciones y metodos para diagnosticar y tratar cancer. |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| EP3029070A1 (fr) | 2009-08-29 | 2016-06-08 | AbbVie Inc. | Protéines de liaison dll4 thérapeutiques |
| JO3183B1 (ar) * | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
-
2011
- 2011-01-23 JO JOP/2011/0021A patent/JO3183B1/ar active
- 2011-01-26 AR ARP110100250A patent/AR080026A1/es unknown
- 2011-01-28 DK DK11701735.0T patent/DK2528945T3/en active
- 2011-01-28 US US13/015,637 patent/US8765125B2/en active Active
- 2011-01-28 SG SG10201500416RA patent/SG10201500416RA/en unknown
- 2011-01-28 MY MYPI2012003169A patent/MY156538A/en unknown
- 2011-01-28 PL PL11701933T patent/PL2528946T3/pl unknown
- 2011-01-28 SG SG10201500404QA patent/SG10201500404QA/en unknown
- 2011-01-28 HU HUE11701735A patent/HUE032985T2/en unknown
- 2011-01-28 US US13/015,652 patent/US8889133B2/en active Active
- 2011-01-28 RS RS20170036A patent/RS55595B1/sr unknown
- 2011-01-28 SI SI201131011A patent/SI2528945T1/sl unknown
- 2011-01-28 CN CN2011800165511A patent/CN102884081A/zh active Pending
- 2011-01-28 MX MX2012008740A patent/MX343553B/es active IP Right Grant
- 2011-01-28 RU RU2012136816/10A patent/RU2587620C2/ru not_active IP Right Cessation
- 2011-01-28 KR KR1020127022506A patent/KR101832118B1/ko active IP Right Grant
- 2011-01-28 MY MYPI2012003168A patent/MY156353A/en unknown
- 2011-01-28 RS RS20170142A patent/RS55715B1/sr unknown
- 2011-01-28 RU RU2012136817/10A patent/RU2587624C2/ru not_active IP Right Cessation
- 2011-01-28 EP EP11701933.1A patent/EP2528946B1/fr active Active
- 2011-01-28 CA CA2787615A patent/CA2787615C/fr active Active
- 2011-01-28 SI SI201131020A patent/SI2528946T1/sl unknown
- 2011-01-28 HU HUE11701933A patent/HUE031432T2/en unknown
- 2011-01-28 SG SG2012052056A patent/SG182528A1/en unknown
- 2011-01-28 KR KR1020127022496A patent/KR101797918B1/ko active IP Right Grant
- 2011-01-28 MX MX2012008638A patent/MX343555B/es active IP Right Grant
- 2011-01-28 EP EP11701735.0A patent/EP2528945B1/fr active Active
- 2011-01-28 BR BR112012018766A patent/BR112012018766A2/pt active Search and Examination
- 2011-01-28 JP JP2012551293A patent/JP5997613B2/ja active Active
- 2011-01-28 PT PT117017350T patent/PT2528945T/pt unknown
- 2011-01-28 PT PT117019331T patent/PT2528946T/pt unknown
- 2011-01-28 CN CN201180016820.4A patent/CN102947336B/zh not_active Expired - Fee Related
- 2011-01-28 LT LTEP11701735.0T patent/LT2528945T/lt unknown
- 2011-01-28 SM SM201600412T patent/SMT201600412B/it unknown
- 2011-01-28 ES ES11701735.0T patent/ES2605430T3/es active Active
- 2011-01-28 PL PL11701735T patent/PL2528945T3/pl unknown
- 2011-01-28 WO PCT/US2011/022810 patent/WO2011094465A1/fr active Application Filing
- 2011-01-28 AU AU2011210773A patent/AU2011210773B2/en active Active
- 2011-01-28 SG SG2012052049A patent/SG182527A1/en unknown
- 2011-01-28 TW TW100103219A patent/TWI564019B/zh not_active IP Right Cessation
- 2011-01-28 CA CA2787394A patent/CA2787394C/fr active Active
- 2011-01-28 UY UY0001033206A patent/UY33206A/es not_active Application Discontinuation
- 2011-01-28 DK DK11701933.1T patent/DK2528946T3/en active
- 2011-01-28 ES ES11701933.1T patent/ES2609663T3/es active Active
- 2011-01-28 LT LTEP11701933.1T patent/LT2528946T/lt unknown
- 2011-01-28 AU AU2011210771A patent/AU2011210771B2/en active Active
- 2011-01-28 BR BR112012018820A patent/BR112012018820A8/pt not_active Application Discontinuation
- 2011-01-28 WO PCT/US2011/022817 patent/WO2011094467A2/fr active Application Filing
- 2011-01-28 TW TW105101963A patent/TWI600433B/zh not_active IP Right Cessation
- 2011-01-28 JP JP2012551294A patent/JP5883801B2/ja active Active
-
2012
- 2012-07-11 IL IL220887A patent/IL220887A/en not_active IP Right Cessation
- 2012-07-11 IL IL220889A patent/IL220889A/en not_active IP Right Cessation
-
2014
- 2014-05-22 US US14/285,409 patent/US20140255429A1/en not_active Abandoned
-
2016
- 2016-11-14 CY CY20161101167T patent/CY1118223T1/el unknown
-
2017
- 2017-01-04 CY CY20171100010T patent/CY1118551T1/el unknown
- 2017-01-16 SM SM201700021T patent/SMT201700021B/it unknown
- 2017-01-26 HR HRP20170130TT patent/HRP20170130T1/hr unknown
- 2017-02-16 HR HRP20170249TT patent/HRP20170249T1/hr unknown
- 2017-03-19 JO JOP/2017/0065A patent/JO3242B1/ar active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL220889A0 (en) | Methods of treating diabetes with dll4 antagonists | |
| HRP20171352T1 (hr) | Wnt-antagonisti i postupci liječenja | |
| EP2675459A4 (fr) | Composés et méthodes de traitement du diabète | |
| IL222778A0 (en) | Diabetes therapy | |
| EP2721063A4 (fr) | Polypeptides liant pcsk9 et leurs procédés d'utilisation | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| EP2558122A4 (fr) | Traitement d'association avec des antagonistes de vegf-c | |
| ZA201205425B (en) | Treatment with vb-201 | |
| EP2867239A4 (fr) | Oxabicycloheptanes et oxabicycloheptènes pour le traitement du diabète | |
| EP2731429A4 (fr) | Composés, procédés de préparation et procédés d'utilisation | |
| IL256026A (en) | Treatment methods | |
| GB201111630D0 (en) | Novel compounds and their use | |
| EP2709999A4 (fr) | Composés de quinazoline-7-éther et méthodes d'utilisation | |
| GB201118026D0 (en) | Biosensor | |
| HK1202819A1 (en) | Treatment of type i and type ii diabetes i ii | |
| GB201115285D0 (en) | Biosensor and uses thereof | |
| HU1000688D0 (en) | Use of trifluoro-phal | |
| GB201110293D0 (en) | Biosensor | |
| GB201104412D0 (en) | Biosensor |